Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
Chih-Tsung
CT
Hung
Chien-Ping
CP
Chiang
Bai-Yao
BY
Wu
D000970:Antineoplastic Agents / Q000009:adverse effects*; D060831:Hand-Foot Syndrome / Q000209:etiology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D011565:Psoriasis / Q000139:chemically induced / Q000532:radiotherapy*; D000077157:Sorafenib; D014467:Ultraviolet Therapy
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib